Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
It is already known from animal studies that the study drug can improve mucosal immunity as
 shown by increased serum and mucosal IgA secretion. This study will evaluate the safety of an
 oral intake of the natural product 2006-RD-05 at the recommended daily dose of 300 mg. In
 addition, this trial will aim to determine if this intake is able ot improve serum and
 salivary IgA synthesis.
Inclusion Criteria:

 -  Men or women aged 18 - 60

 -  In good health

 -  BMI between 20 and 30 kg/m2

 -  Non-smoking

 Exclusion Criteria:

 -  Allergic to study drug

 -  Use of immune-modulating drugs

 -  Uncontrolled hypertension (Systolic > 140 or diastolic > 90)

 -  Women of childbearing age not using proper contraception, that is pregnant or
 breastfeeding